Peritoneal mesothelioma: Treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy;Mésothéliome péritonéal: Traitement par l'association chirurgie de cytoréduction et chimiothérapie hyperthermique intrapéritonéale

Journal de Chirurgie

Volumn 145, Issue 5, 2008, Pages 447-453

  Passot, G ^a   Cotte, E ^a   Brigand, C ^b   Beaujard, A C ^c   Isaac, S ^c   Gilly, F N ^a   Glehen, O ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c Service d'Anesthésie Réanimation   (France)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal mesothelioma; Treatment

Indexed keywords

EID: 58149504316     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(08)74654-4     Document Type: Article

References (38)

1. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2006.
2. Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003; 12:605-621.
3. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988;93: 159-162.
4. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-153.
5. Mentzer SJ, Antman KH, Attinger C, et al. Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung. J Surg Oncol 1993;53:54-59.
6. Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003;12:649-671.
7. Gilly FN, Cotte E, Brigand C, et al. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 2006;32:597-601.
8. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-374.
9. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790-796.
10. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-731.
11. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29-42.
12. National Cancer Institute Common Toxicity Criteria. Version 2.0, March 1998. 9 (available at http://ctep.cancer.gov/reporting/ctc.html).
13. Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2007;14:500-508.
14. van Ruth S, Bronkhorst MW, van Coevorden F, et al. Peritoneal benign cystic mesothelioma: a case report and review of the literature. Eur J Surg Oncol 2002;28:192-195.
15. Zoetmulder FA, van Ruth S. Response to correspondence from Kauimarz Sethna, Faheez Mohamed and Paul H. Sugarbaker, EJSO 2002;28:897. Eur J Surg Oncol 2003;29: 480.
16. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948-953.
17. Gilks B, Hegedus C, Freeman H, et al. Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 1988;61:2019-2021.
18. Bochetta M, Di Resta I, Powwers A. Human mesothelioma cells are unsusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 2000;97:10214-10219.
19. Peterson JT Jr, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma. A review. Cancer 1984;54:951-960.
20. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982;96: 746-755.
21. Maurer R. Egloff B. Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 1975;36: 1381-1385.
22. Roushdy-Hammady I. Contested etiology: cancer risk among two Anatolian populations in Turkey and Europe. Cult Med Psychiatry 2004;28:315-339.
23. Rogoff EE, Hilaris BS, Huvos AG. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 1973;32:656-664.
24. Sridhar KS, Doria R, Raub WA Jr, et al. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70:2969-2979.
25. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:676-681.
26. Rose RG, Palmer JD, Lougheed MN. Treatment of peritoneal mesothelioma with radioactive colloidal gold; report of a case. Cancer 1955;8:478-481.
27. Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996;81:193-211.
28. Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007;18:827-834.
29. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219-228.
30. Yan TD, Edwards G, Alderman R, et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma - a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 14:515-525.
31. Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007;14:41-49.
32. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547-550.
33. Yates DH, Corrin B, Stidolph PN. Malignant mesothelioma in south east England: Clinicapathological experienca of 272 cases. Thorax 1997;52:507-512.
34. Neumann V, Muller KM, Fischer M. [Peritoneal mesothelioma - incidence and etiology]. Pathologe 1999;20:169-176.
35. Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70:6-12.
36. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999;6:582-590.
37. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-4567.
38. Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006;13:405-412.